Pharmacological treatment of depression in women with breast cancer: A systematic review

Breast Cancer Research and Treatment

Volumn 141, Issue 3, 2013, Pages 325-330

  Andersen, Lærke Toftegård ^a   Hansen, Melissa Voigt ^a   Rosenberg, Jacob ^a   Gögenur, Ismail ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antidepressants; Breast cancer; Depression; Depressive symptoms; Oncology; Pharmacological treatment

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; MIANSERIN; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE;

BREAST CANCER; DEPRESSION; FUNCTIONAL ASSESSMENT OF CANCER THERAPY; FUNCTIONAL LIVING INDEX CANCER; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; OPEN STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ZUNG SELF RATING DEPRESSION SCALE;

ANTIDEPRESSIVE AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DEPRESSION; FEMALE; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84887074043     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2708-6     Document Type: Review

References (49)

1. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330:702
2. Suppli NP, Deltour I, Damkjaer LH, Christensen J, Jensen AB, Kroman NT, Johansen C, Dalton SO (2011) Factors associated with the prescription of antidepressive medication to breast cancer patients. Acta Oncol 50:243-251. doi: 10.3109/0284186X.2010.531049
3. Azzone V, Frank RG, Pakes JR, Earle CC, Hassett MJ (2009) Behavioral health services for women who have breast cancer. J Clin Oncol 27:706-712. doi: 10.1200/JCO.2008.16.3006
4. Ashbury FD, Madlensky L, Raich P, Thompson M, Whitney G, Hotz K, Kralj B, Edell WS (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278-285
5. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160-174. doi: 10.1016/S1470-2045(11) 70002-X
6. Dalton SO, Laursen TM, Ross L, Mortensen PB, Johansen C (2009) Risk for hospitalization with depression after a cancer diagnosis: a nationwide, population-based study of cancer patients in Denmark from 1973 to 2003. J Clin Oncol 27:1440-1445. doi: 10.1200/JCO.2008.20.5526
7. Fallowfield L, Ratcliffe D, Jenkins V, Saul J (2001) Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 84:1011-1015
8. Dantzer R (2009) Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 29:247-264. doi: 10.1016/j.iac.2009.02.002
9. Fann JR, Thomas-Rich AM, Keaton WJ, Cowley D, Pepping M, McGregor BA, Gralow J (2008) Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 30:112-126. doi: 10.1016/j.genhosppsych.2007. 10.008
10. Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG (1998) A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 7:291-300
11. Ng CG, Boks MPM, Zainal NZ, De Wit NJ (2011) The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord 131:1-7. doi: 10.1016/j.jad.2010.07.034
12. Bray F, Ren JS, Masuyer A, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133-1145. doi: 10.1002/ijc.27711
13. Rosso S, Gondos A, Zanetti R, Bray F, Zakelj M, Zagar T, Smailyte G, Ponti A, Brewster DH (2010) Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 46:3351-3357. doi: 10.1016/j.ejca.2010.09.019
14. Autier P, Boniol M, La Vecchia C, LaVecchia C, Vatten L, Gavin A, Héry C, Heanue M (2010) Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 341:c3620. doi: 10.1136/bmj.c3620
15. Rowland JH, Hewitt M, Ganz PA (2006) Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol 24:5101-5104
16. Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54:269-282
17. Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115:5349-5361. doi: 10.1002/cncr.24561
18. Hjerl K, Andersen EW, Keiding N, Mouridsen HT, Mortensen PB, Jørgensen T (2003) Depression as a prognostic factor for breast cancer mortality. Psychosomatics 44:24-30
19. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101-2107
20. Somerset W, Stout SC, Miller AH, Musselman D (2004) Breast cancer and depression. Oncology 18:1021-1034
21. Meade E, Dowling M (2012) Early breast cancer: diagnosis, treatment and survivorship. Br J Nurs 21:S4-8, S10
22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. doi: 10.1371/journal.pmed.1000100
23. Navari RM, Brenner MC, Wilson MN (2008) Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 112:197-201
24. Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB (2006) A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 67:288-296
25. Van Heeringen K, Zivkov M (1996) Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 169:440-443
26. Pezzella G, Moslinger-Gehmayr R, Contu A (2001) Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70:1-10
27. Park HY, Lee B-J, Kim J-H, Bae J-N, Hahm B-J (2012) Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial. Prog Neuropsychopharmacol Biol Psychiatry 36:318-323. doi: 0.1016/j.pnpbp.2011.11.010
28. Grassi L, Biancosino B, Marmai L, Righi R (2004) Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry 65:515-520
29. Papakostas GI (2008) Tolerability of modern antidepressants. J Clin Psychiatry 69:8-13
30. Baldwin DS, Montgomery SA, Nil R, Lader M (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73-84
31. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA (2011) Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006528
32. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075
33. Breitbart W (2011) Do antidepressants reduce the effectiveness of tamoxifen? Psychooncology 20:1-4. doi: 10.1002/pon.1872
34. Desmarais JE, Looper KJ (2009) Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 70:1688-1697. doi: 10.4088/JCP.08r04856blu
35. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693. doi: 10.1136/bmj.c693
36. Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Biallik M, Loebstein R (2011) Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125:505-510. doi: 10.1007/s10549-010-1008-7
37. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M (2008) Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 165:1251-1255. doi: 10.1176/appi.ajp.2008.08040482
38. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332:385-393
39. Hickie IB, Rogers NL (2011) Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621-631. doi: 10.1016/S0140-6736(11)60095-0
40. De Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628-642. doi: 10.1038/nrd3140
41. Acil M, Basgul E, Celiker V, Karagöz AH, Demir B, Aypar U (2004) Perioperative effects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance. Eur J Anaesthesiol 21:553-557
42. Hofmann SG, Sawyer AT, Witt AA, Oh D (2010) The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol 78:169-183. doi: 10.1037/a0018555
43. Zainal NZ, Booth S, Huppert FA (2012) The efficacy of mindfulness-based stress reduction on mental health of breast cancer patients: a meta-analysis. Psychooncology. doi: 10.1002/pon.3171
44. Cramer H, Lauche R, Paul A, Dobos G (2012) Mindfulness-based stress reduction for breast cancer-a systematic review and meta-analysis. Curr Oncol 19:343-352. doi: 10.3747/co.19.1016
45. Piet J, Würtzen H, Zacharia R (2012) The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and suvivors: a systematic review and meta-analysis. J Consult Clin Psychol 80:1007-10020. doi: 10.1037/a0028329
46. Lengacher CA, Johnson-Mallard V, Post-White J, Moscoso MS, Jacobsen PB, Klein TW, Widen RH, Fitzgerald SG, Shelton MM, Barta M, Goodman M, Cox CE, Kip KE (2009) Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology 18:1261-1272. doi: 10.1002/pon.1529
47. Henderson VP, Clemow L, Massion AO, Hurley TG, Druker S, Hébert JR (2012) The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial. Breast Cancer Res Treat 131:99-109. doi: 10.1007/s10549-011-1738-1
48. Würtzen H, Dalton SO, Elsass P, Sumbundu AD, Steding-Jensen M, Karlsen RV, Andersen KK, Flyger HL, Pedersen AE, Johansen C (2013) Mindfulness significantly reduces self-reported levels of anxiety and depression: results of a randomised controlled trial among 336 Danish women treated for stage I-III breast cancer. Eur J Cancer 49:1365-1373. doi: 10.1016/j.ejca.2012.10.030
49. Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholla PG, Harrington JE, Thomas PW (2012) Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 30:1335-1342. doi: 10.1200/JCO.2010.34.033.1